289 related articles for article (PubMed ID: 8804493)
1. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials.
Boyle P; Gould AL; Roehrborn CG
Urology; 1996 Sep; 48(3):398-405. PubMed ID: 8804493
[TBL] [Abstract][Full Text] [Related]
2. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
3. Finasteride for benign prostatic hyperplasia.
Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
5. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C
JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264
[TBL] [Abstract][Full Text] [Related]
6. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
Wilt TJ; Howe W; MacDonald R
BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized clinical trials of finasteride.
Roehrborn CG
Urology; 1998 Apr; 51(4A Suppl):46-9. PubMed ID: 9586596
[TBL] [Abstract][Full Text] [Related]
8. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
9. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients.
Tewari A; Shinohara K; Narayan P
Urology; 1995 Feb; 45(2):258-64; discussion 265. PubMed ID: 7531900
[TBL] [Abstract][Full Text] [Related]
10. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
[TBL] [Abstract][Full Text] [Related]
11. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
[TBL] [Abstract][Full Text] [Related]
12. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
Kaplan SA; Roehrborn CG; McConnell JD; Meehan AG; Surynawanshi S; Lee JY; Rotonda J; Kusek JW; Nyberg LM;
J Urol; 2008 Sep; 180(3):1030-2; discussion 1032-3. PubMed ID: 18639298
[TBL] [Abstract][Full Text] [Related]
14. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
15. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ; Howe RW
BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
17. 5alpha-reductase inhibitors: what role should they play?
Kaplan SA
Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM
CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291
[TBL] [Abstract][Full Text] [Related]
19. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
Ekman P
Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
[TBL] [Abstract][Full Text] [Related]
20. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R
Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]